EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.

Autor: Batra U; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. Electronic address: ullasbatra@gmail.com., Sharma M; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India., Amrith BP; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India., Mehta A; Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India., Jain P; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2020 Nov; Vol. 21 (6), pp. e597-e600. Date of Electronic Publication: 2020 May 23.
DOI: 10.1016/j.cllc.2020.05.016
Databáze: MEDLINE
Externí odkaz: